UBS Initiates Coverage on Baxter Int'l (BAX) with a Buy
More News related to BAX
- David Moenning's Daily State of the Markets: 11/24
- Relational Investors Raises Stakes In Yahoo! (YHOO) and Sun Microsystems (JAVA), Shows New Stake In Schering-Plough (SGP)
- Baxter International (BAX) Boosts Qt Dividend 20% to $0.26/Sh
- Baxter Declares Quarterly Dividend, Increases Rate 20 Percent
- AmeriCares Launches India Operations
More News related to New Coverage
- After-Hours Movers 12/05: Actuate (ACTU) Up On Higher Tender Offer, RF Micro (RFMD) Lower on Guidance
- Trading Radar for 12/05: Big Lots (BIG), Flow Int'l (FLOW), Blyth (BTH) Report; Nonfarm Payrolls, Unemployment Rate, Consumer Credit Due
- Unusual 11 Mid-Day Movers 12/04: DXCM, TLB, PRKR, PSS Higher; CRUS, DMND, ITWO, DDMX Lower
- Notable Analyst Rating Changes 12/04: AMZN, YRCW, GPN, TRI Upgraded; DMND, DOX, FMCN, ISIL Downgraded
- Morning Movers 12/04: Merck (MRK) Lower On Guidance, Amazon.com (AMZN) Higher On Upgrade
UBS initiates coverage on Baxter Int'l (NYSE: BAX) with a Buy.
Baxter International Inc. (Baxter) develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.
Related Categories
New CoverageStocks Mentioned
-1.58Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
